TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
TScan Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.21−0.02 (-9.00%)
Close on Oct 19, 2026
- Market cap
- $27.32M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
53.5%
36M of 68M shares
Institutional holders
60
7 new, 7 sold out
Net institutional buying
4M
In Q2 2026
Insider trades, 12 months
3 buys · 0 sales
Net bought $145.62K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Lynx1 Capital Management LP | 7,857,347 | 15.00% | 13G (passive) amendment | Jun 30, 2025 |
| Bvf Inc/Il | 6,417,831 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| Lampert Mark N | 5,263,541 | 9.99% | 13G (passive) amendment | Mar 31, 2025 |
| Parag Shah | 3,602,700 | 6.90% | 13G (passive) amendment | Dec 31, 2024 |
| Phillip Gross | 3,500,000 | 7.13% | 13G (passive) amendment | Dec 31, 2024 |
| Readout Capital, LP | 3,453,388 | 5.40% | 13G (passive) | Sep 21, 2026 |
| Felix J. Baker | 2,828,938 | 6.10% | 13D (active) amendment | Apr 19, 2024 |
| Weston Nichols | 20,519,148 | 13.10% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TCRX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 8,019,148 | 11.83% | $7.86M | – | 0.91% |
| Bvf Inc/Il | 5,564,290 | 8.21% | $5.45M | – | 0.14% |
| Baker Bros. Advisors LP | 2,784,792 | 4.11% | $2.73M | – | 0.01% |
| Vanguard Capital Management LLC | 2,158,831 | 3.19% | $2.12M | +4,575 | 0.00% |
| Two Sigma Investments, LP | 1,949,604 | 2.88% | $1.91M | +740,595 | 0.00% |
| Renaissance Technologies LLC | 1,326,799 | 1.96% | $1.30M | −37,984 | 0.00% |
| Acadian Asset Management LLC | 1,305,840 | 1.93% | $1.28K | +1,103,853 | 0.00% |
| Deer Management Co. LLC | 1,245,504 | 1.84% | $1.22M | – | 0.15% |
| Millennium Management LLC | 1,163,611 | 1.72% | $1.14M | −296,674 | 0.00% |
| Jacobs Levy Equity Management, Inc | 1,049,806 | 1.55% | $1.03M | +241,450 | 0.00% |
| Citadel Advisors LLC | 1,009,107 | 1.49% | $989.03K | +690,696 | 0.00% |
| BlackRock, Inc. | 994,654 | 1.47% | $974.86K | −846,298 | 0.00% |
| Kalehua Capital Management LLC | 909,752 | 1.34% | $891.65K | New | 0.28% |
| Boothbay Fund Management, LLC | 772,241 | 1.14% | $756.87K | New | 0.01% |
| Marshall Wace, Llp | 687,364 | 1.01% | $673.62K | +450,018 | 0.00% |
| DC Funds, LP | 630,000 | 0.93% | $617.46K | – | 49.27% |
| Geode Capital Management, LLC | 584,811 | 0.86% | $573.40K | −32,141 | 0.00% |
| D. E. Shaw & Co., Inc. | 548,402 | 0.81% | $537.49K | +228,815 | 0.00% |
| Gsa Capital Partners Llp | 548,087 | 0.81% | $537 | +169,127 | 0.03% |
| Vanguard Fiduciary Trust Co | 363,954 | 0.54% | $356.68K | +58,182 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 60 | 36M | 53.5% | 7 / 23 | 12 / 7 | 6M | 2M |
| Q1 2026 | 60 | 33M | 48.0% | 11 / 15 | 21 / 11 | 6M | 2M |
| Q4 2025 | 61 | 31M | 45.3% | 10 / 18 | 19 / 20 | 3M | 7M |
| Q3 2025 | 73 | 35M | 51.7% | 5 / 19 | 30 / 12 | 1M | 2M |
| Q2 2025 | 81 | 36M | 52.8% | 21 / 26 | 18 / 32 | 7M | 11M |
| Q1 2025 | 92 | 40M | 59.2% | 17 / 33 | 19 / 13 | 4M | 5M |
| Q4 2024 | 89 | 42M | 61.3% | 16 / 31 | 15 / 16 | 3M | 4M |
| Q3 2024 | 89 | 42M | 61.8% | 20 / 25 | 18 / 11 | 7M | 2M |
| Q2 2024 | 81 | 41M | 61.2% | 32 / 18 | 15 / 16 | 9M | 2M |
| Q1 2024 | 66 | 35M | 51.4% | 17 / 23 | 8 / 5 | 3M | 0M |
| Q4 2023 | 54 | 32M | 47.5% | 22 / 13 | 4 / 0 | 4M | 0M |
| Q3 2023 | 32 | 29M | 42.2% | 6 / 10 | 1 / 1 | 1M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of TCRX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,500,337 | 2.21% | $1.47M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 575,570 | 0.85% | $564.12K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 293,642 | 0.43% | $317.13K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 167,533 | 0.25% | $164.20K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 87,566 | 0.13% | $94.57K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 72,914 | 0.11% | $78.75K | 0.00% | May 31, 2026 |
| Ultra-Small Company Market Fund | 70,400 | 0.10% | $69.00K | 0.05% | Jun 30, 2026 |
| Multi-Manager Small Cap Equity Strategies Fund | 69,487 | 0.10% | $75.05K | 0.01% | May 31, 2026 |
| Small Cap Equity Fund | 65,813 | 0.10% | $64.50K | 0.01% | Jun 30, 2026 |
| NVIT Multi-Manager Small Company Fund | 44,500 | 0.07% | $43.61K | 0.01% | Jun 30, 2026 |
| NVIT Small Cap Value Fund | 39,000 | 0.06% | $38.22K | 0.02% | Jun 30, 2026 |
| Strategic Advisers U.S. Total Stock Fund | 29,612 | 0.04% | $31.98K | 0.00% | May 31, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 29,605 | 0.04% | $29.02K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 28,767 | 0.04% | $31.07K | 0.00% | May 31, 2026 |
| Vanguard Balanced Index Fund | 19,320 | 0.03% | $18.94K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Gavin MacBeath | Chief Executive Officer, Director | 49,767 | 0.07% | Jan 22, 2026 |
| Jason Amello | Chief Financial Officer | – | – | Jan 22, 2026 |
| Zoran Zdraveski | See Remarks | 67,111 | 0.10% | Jan 22, 2026 |
| Chrystal Louis | Chief Medical Officer | – | – | Jan 22, 2026 |
| Leiden Dworak | See Remarks | 5,692 | 0.01% | Jan 22, 2026 |
| Bros. Advisors (GP) LLC Baker | Director | – | – | May 22, 2026 |
| Keith Woods | Director | – | – | May 22, 2026 |
| 667, L.P. | Director | 256,209 | 0.38% | May 22, 2026 |
| Katina Dorton | Director | – | – | May 22, 2026 |
| Garry A. Nicholson | Director | – | – | May 22, 2026 |
| Gabriela Gruia | Director | – | – | May 22, 2026 |
| Barbara Klencke | Director | 70,000 | 0.10% | May 22, 2026 |
| Bros. Advisors Lp Baker | Director | – | – | May 22, 2026 |
| Julian Baker | Director | – | – | May 22, 2026 |
| Felix Baker | Director | – | – | May 22, 2026 |
| Brothers Life Sciences LP Baker | Director | – | – | May 22, 2026 |
| Weston Nichols | 10% owner | 5,357,347 | 7.90% | Dec 23, 2025 |
| Capital Management LP Lynx1 | 10% owner | 8,019,148 | 11.83% | Dec 23, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Capital Management LP Lynx1 10% owner | Dec 23, 2025 | Buy | +6,232 | $0.90 | $5.61K | 8,019,148 |
| Capital Management LP Lynx1 10% owner | Dec 22, 2025 | Buy | +75,500 | $0.90 | $67.95K | 8,012,916 |
| Capital Management LP Lynx1 10% owner | Dec 19, 2025 | Buy | +80,069 | $0.90 | $72.06K | 7,937,416 |
| Capital Management LP Lynx1 10% owner | May 20, 2025 | Buy | +1,200,000 | $1.20 | $1.44M | 7,946,141 |
| Capital Management LP Lynx1 10% owner | May 19, 2025 | Buy | +1,388,794 | $1.20 | $1.67M | 6,746,141 |
| Weston Nichols 10% owner | Dec 13, 2024 | Buy | +100,000 | $2.90 | $290.00K | 5,357,347 |
| Weston Nichols 10% owner | Dec 12, 2024 | Buy | +31,800 | $3.01 | $95.72K | 5,257,347 |
| Weston Nichols 10% owner | Nov 15, 2024 | Buy | +947 | $4.34 | $4.11K | 5,225,547 |
| Barbara Klencke Director | Sep 23, 2024 | Buy | +5,000 | $5.29 | $26.45K | 45,000 |
| Barbara Klencke Director | Aug 26, 2024 | Buy | +5,000 | $5.53 | $27.65K | 40,000 |
| Zoran Zdraveski See Remarks | Aug 23, 2024 | Option exercise | +54,895 | $4.85 | $266.24K | 67,111 |
| Zoran Zdraveski See Remarks | Aug 23, 2024 | Option exercise | +25,000 | $3.27 | $81.75K | 92,111 |
| Zoran Zdraveski See Remarks | Aug 23, 2024 | Option exercise | +13,125 | $1.81 | $23.76K | 105,236 |
| Zoran Zdraveski See Remarks | Aug 23, 2024 | Option exercise | +64,166 | $2.49 | $159.77K | 169,402 |
| Zoran Zdraveski See Remarks | Aug 23, 2024 | Sale | −164,686 | $5.78 | $951.89K | 4,716 |
| Barbara Klencke Director | Aug 23, 2024 | Buy | +5,000 | $5.69 | $28.45K | 35,000 |
| Timothy J. Barberich Director | Dec 19, 2023 | Buy | +317 | $4.97 | $1.58K | 67,027 |
| Timothy J. Barberich Director | Dec 18, 2023 | Buy | +28,830 | $4.89 | $140.98K | 66,710 |
| Barbara Klencke Director | Dec 14, 2023 | Buy | +5,000 | $5.08 | $25.40K | 30,000 |
| Timothy J. Barberich Director | Jun 2, 2023 | Buy | +37,880 | $2.63 | $99.62K | 37,880 |
| Capital Management LP Lynx1 10% owner | May 31, 2023 | Sale | −15,000 | $2.52 | $37.80K | 5,225,000 |
| Capital Management LP Lynx1 10% owner | May 31, 2023 | Sale | −10,000 | $2.51 | $25.10K | 5,240,000 |
| Capital Management LP Lynx1 10% owner | May 31, 2023 | Sale | −400 | $2.51 | $1.00K | 5,224,600 |
| Brian M. Silver Chief Financial Officer | Dec 28, 2022 | Buy | +3,158 | $1.56 | $4.93K | 32,885 |
| Brian M. Silver Chief Financial Officer | Dec 27, 2022 | Buy | +2,842 | $1.50 | $4.26K | 29,727 |
| David P. Southwell Chief Executive Officer, Director | May 18, 2022 | Buy | +10,000 | $3.55 | $35.50K | 171,569 |
| David P. Southwell Chief Executive Officer, Director | May 18, 2022 | Buy | +15,000 | $3.62 | $54.30K | 161,569 |
| 667, L.P. Director, 10% owner | May 11, 2022 | Buy | +2,882 | $1.99 | $5.74K | 256,209 |
| 667, L.P. Director, 10% owner | May 11, 2022 | Buy | +22,983 | $1.99 | $45.74K | 2,528,583 |
| 667, L.P. Director, 10% owner | May 10, 2022 | Buy | +101,831 | $1.93 | $196.53K | 1,747,506 |
| 667, L.P. Director, 10% owner | May 10, 2022 | Buy | +40,800 | $1.70 | $69.36K | 145,498 |
| 667, L.P. Director, 10% owner | May 10, 2022 | Buy | +758,094 | $1.95 | $1.48M | 2,505,600 |
| 667, L.P. Director, 10% owner | May 10, 2022 | Buy | +95,060 | $1.95 | $185.37K | 253,327 |
| 667, L.P. Director, 10% owner | May 10, 2022 | Buy | +12,769 | $1.93 | $24.64K | 158,267 |
| 667, L.P. Director, 10% owner | May 10, 2022 | Buy | +325,373 | $1.70 | $553.13K | 1,645,675 |
| Brian M. Silver Chief Financial Officer | Mar 24, 2022 | Buy | +15,000 | $3.40 | $51.00K | 26,885 |
| David P. Southwell Chief Executive Officer, Director | Dec 23, 2021 | Option exercise | +48,670 | $1.97 | $95.88K | 146,569 |
| Zoran Zdraveski Chief Legal Officer | Sep 23, 2021 | Buy | +4,716 | $7.48 | $35.28K | 4,716 |
| Gavin MacBeath Chief Scientific Officer | Sep 21, 2021 | Buy | +57 | $6.19 | $353 | 49,767 |
| Brian M. Silver Chief Financial Officer | Sep 21, 2021 | Buy | +5,000 | $6.32 | $31.60K | 11,885 |
| Gavin MacBeath Chief Scientific Officer | Sep 20, 2021 | Buy | +4,943 | $6.22 | $30.75K | 49,710 |
| Brian M. Silver Chief Financial Officer | Sep 9, 2021 | Buy | +5,885 | $8.48 | $49.90K | 6,885 |
| David P. Southwell Chief Executive Officer, Director | Sep 8, 2021 | Buy | +11,000 | $8.73 | $96.03K | 97,899 |
| William Desmarais Chief Business Officer | Aug 27, 2021 | Buy | +2,500 | $9.08 | $22.70K | 2,500 |
| 667, L.P. Director | Jul 20, 2021 | Buy | +1,320,302 | $15.00 | $19.80M | 1,320,302 |
| 667, L.P. Director | Jul 20, 2021 | Buy | +104,698 | $15.00 | $1.57M | 104,698 |
| Timothy J. Barberich Director | Jul 20, 2021 | Conversion | +33,259 | – | – | 33,259 |
| Brian M. Silver Chief Financial Officer | Jul 20, 2021 | Buy | +1,000 | $15.00 | $15.00K | 1,000 |
| Christoph H. Westphal 10% owner | Jul 20, 2021 | Buy | +133,333 | $15.00 | $2.00M | 1,278,838 |
| Christoph H. Westphal 10% owner | Jul 20, 2021 | Conversion | +1,145,505 | – | – | 1,145,505 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Zoran Zdraveski Officer | Aug 23, 2024 | 164,686 | $905.77K | Aug 23, 2024 | STOCK OPTION EXERCISE |
| David P. Southwell Director | May 15, 2023 | 85,911 | $346.22K | May 15, 2023 | Open Market |